Lead project RLYB211 in development for the prevention of FNAIT.


Rallybio is a biopharmaceutical company focused on identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders.

Rallybio acquired it’s lead product candidate, RLYB211, from Prophylix AS in 2019.

RLYB211 is in development for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT) and the company plan to initiate a Phase 1/2 clinical study in the second half of 2020.

The Company’s mission is being advanced by a team of highly experienced biopharma industry leaders with extensive research, development, and rare disease expertise.

Rallybio’s headquarters are in New Haven, Connecticut, USA, with an additional facility at the University of Connecticut’s Technology Incubation Program in Farmington, Connecticut.

Press release dated May 19, 2020.


For more information, please visit www.rallybio.com.